

Full Name:

DOB:

Sex:

Address:

Phone/Mobile

Medicare No:

Appointment Date & Time (NIV Use Only):

Interpreter required? ☐ Yes ☐ No

Language requested:

Category: ☐ OP ☐ ED ☐ IP

Patient Location: Unit: Bed:

## Requesting Consultant (All fields MUST be completed)

Full Name:

Provider no.:

Contact/Pager#:

Signature:

Unit/Specialty:

Date:

Copy Results to:

## Clinical details

### REQUESTED TRACER

- ☐ <sup>18</sup>F-DG ☐ <sup>18</sup>F-PSMA  
☐ DOTATATE ☐ .....

### DIABETIC STATUS

- ☐ Nil ☐ Insulin-dependent  
☐ Diet-controlled ☐ Non-insulin dependent

Diabetic Medication(s): .....

Primary site of disease: .....

Histopathology: .....

Patient Weight: ..... kg

Surgery type .....

Surgery date .....

### Chemotherapy

Last Tx ..... Next Tx .....

### Radiotherapy

Last Tx ..... Next Tx .....

### Previous Imaging

CT: ...../...../..... at .....

MRI: ...../...../..... at .....

PET: ...../...../..... at .....

## Clinical Question(s) & History

Date scan required by (optional):

## Clinical Indications

### DIAGNOSIS/STAGING

- ☐ **Solitary Pulmonary Nodule**  
Evaluation for cases with unsuitable for or failed biopsy
- ☐ **Non-small Cell Lung Cancer**  
Staging of new diagnosis
- ☐ **Head and Neck Cancer**  
Staging of new diagnosis
- ☐ **Oesophageal/Gastro-oesophageal Junction Ca.**  
Staging of cancer considered for active therapy
- ☐ **Lymphoma**  
Staging of new diagnosis or previously untreated
- ☐ **Squamous Cell Carcinoma**  
unknown primary site in cervical lymph nodes
- ☐ **Uterine Cervix Cancer**  
Primary staging prior to RT or combined therapy
- ☐ **Sarcoma (except GIST)**  
Initial staging for biopsy proven sarcoma
- ☐ **Breast Cancer**  
Staging of locally advanced (Stage III) ca. for active therapy
- ☐ **Rare or uncommon cancers (once per dx)**  
<12 cases per 100,000 persons/year; typically, FDG-avid.

### REGSTAGING/MONITOR

- ☐ **Colorectal Cancer**  
Suspected residual/MET(s)/recurrence for active therapy
- ☐ **Metastatic Melanoma**  
Following initial therapy; suspected metastasis/recurrence
- ☐ **Head and Neck Cancer**  
Suspected residual/recurrence after therapy
- ☐ **Lymphoma**  
Assess response within 3 months of first-line therapy
- ☐ **Lymphoma**  
Considered stem cell transplantation; post 2-line therapy
- ☐ **Lymphoma**  
Restaging following confirmation of HL/NHL recurrence
- ☐ **Uterine Cervix Cancer**  
Recurrence cancer for staging
- ☐ **Sarcoma (except GIST)**  
Suspected residual/recurrence after definitive therapy
- ☐ **Breast Cancer**  
Suspected Mets/recurrence; suitable for active therapy
- ☐ **Ovarian Cancer**  
Following initial therapy, suitable for active therapy

# Other PET/CT indications

## Prostate Cancer

PSA level ..... Date ..... Gleason Score .....

☐ **Initial Staging (max. once per lifetime)**

Initial staging of intermediate to high-risk prostate cancer.  
Previously untreated and considered suitable for locoregional therapy with curative intent

☐ **Restaging (max. twice per lifetime)**

- PSA ↑ 2ng/ml above nadir post-RT
- OR failure in PSA ↓ to undetectable levels
- OR PSA after radical prostatectomy

## GEP Neuroendocrine Tumours

Somatostatin Receptor (SSR) therapy – next injection due .....

☐ **GEP Neuroendocrine tumour**

Staging of suspected ca on the basis of biochemical evidence with negative or equivocal imaging; or surgically amenable GEP tumour identified and PET scan to exclude additional disease sites.

## <sup>18</sup>FDG Brain Indications

☐ **Alzheimer's Disease (max. 3 per lifetime)**

For diagnosis and quantitative assessment; equivocal findings determined by, or in consultation with, a clinical specialist; where a previous FDG Brain scan or NM SPECT-CT Brain scan has not been performed in the past 12 months.

☐ **Brain Tumour**

Evaluate suspected/residual/recurrence post-therapy (or with ongoing chemo); considered suitable for further therapy.

☐ **Refractory Epilepsy**

For refractory epilepsy being evaluated for surgery

☐ **Other Indication: .....**

Indications not listed on the Medicare Benefits Schedule may incur an out-of-pocket cost, with exception for Northern Health-referred patients. Please contact the PET Team on **8405 9600** for further information.

☐ **Request for Diagnostic CT (in addition to PET/CT)**

☐ CT Brain ☐ CT-Chest Abdomen Pelvis ☐ CT-IVP

Indication for Diagnostic CT .....

Examination/Body region requested for scanning .....

## Diagnostic Imaging Use Only

### Patient identification & procedure matching

☐ Full name ☐ D.O.B. ☐ Address

Correct examination: ☐ Y ☐ N

Correct side / site: ☐ Y ☐ N ☐ N/A

☐ Ward / Staff / Relative assisted with patient identification

The following processes have been confirmed prior to commencing:

☐ Justification ☐ Optimisation ☐ Approval ☐ Consent

Name & Position:

Signature:

### Patient Pregnancy & Breastfeeding Checklist

Pregnancy Status: ☐ Y ☐ N

Gestational age: .....

LMP: .....

Breastfeeding: ☐ Y ☐ N ☐ N/A

Patient signature:

## Technologist notes

Your doctor has recommended you to use **Northern Imaging Victoria**.  
Please discuss with your doctor before choosing a different imaging provider.